Project Grant R01CA318002
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $646K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- Federal Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct fundamental research on therapeutic targeting of SMARCAL1 in therapy-resistant gliomas. The award, effective April 1, 2026 through March 31, 2031, supports investigation of SMARCAL1 as a synthetic lethal vulnerability in Alternative Lengthening of Telomeres (ALT)-positive...
- Federal Grant Award Summary Duke University's Office of Research Administration was awarded $402,135 by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, with completion targeted for April 30, 2029. The project involves the development and optimization of SCHICAR (Single-Cell High-resolution 3D Genome Interactions, Chromatin Accessibility, and transcRiptomes), a novel tri-modal single-cell platform designed to simultaneously capture...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $610,459 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, with completion anticipated by April 30, 2031. This five-year award funds fundamental research investigating NEUROD1 and cell fate plasticity in olfactory neuroblastoma (ONB), a rare and aggressive tumor with limited treatment options. The research...
- Federal Project Grant Award Summary Duke University, through its Office of Research Administration, received a $607,157 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) beginning May 1, 2026 and concluding April 30, 2031. This five-year research initiative will deliver fundamental cancer biology research aimed at understanding neuroendocrine prostate cancer (NEPC) mechanisms and identifying therapeutic targets. Specifically, the...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $179,276 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2025, with a completion date of May 31, 2027. The award supports research investigating the role of the ABL kinase-regulated HIF-1A-TAZ signaling pathway in promoting brain metastasis in triple-negative breast cancer (TNBC). The project deliverables include...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.88 million Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on September 23, 2025, with completion targeted for August 31, 2029. The award supports fundamental research integrating genome-wide association study (GWAS) data with single-cell omics technologies to identify and characterize the cellular effectors underlying...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $302,524 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on September 10, 2025, with completion expected by April 30, 2028. This F32 postdoctoral fellowship grant funds biomedical research training and career development in cancer research, supporting an investigator's research into the role of SMARCAL1 depletion in enhancing...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $501,422 Project Grant under the Cancer Biology Research program (CFDA 93.396) commencing May 1, 2026, with completion targeted for April 30, 2031. This award supports fundamental research to advance understanding of synthetic lethal (SL) vulnerabilities in specific cancer subtypes, with the ultimate objective of developing novel precision oncology therapeutics. The research...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $411,152 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 5, 2025, with completion targeted for August 31, 2027. This research initiative focuses on identifying and validating noncovalent protein interactions of mutant KRAS (MKRAS) inhibitors, addressing a critical gap in understanding off-target effects of recently FDA-approved...